Saturday, October 10, 2026 - Virtual Agenda

Annual Meeting of Members

Damon L. Baker, DO, MACOI, Professor and Chair Department of Internal Medicine, Oklahoma State University Center for Health Sciences

Florida Statute 456
Florida Statute 459
Rule 64B15

Learning Objectives:

• Identify the Florida statutes and Board Rules governing osteopathic physicians.
• Recognize recent legislative and regulatory changes affecting medical practice.
• Understand the Department of Health’s investigative and disciplinary process.

Jason D. Winn, Esquire, Attorney, Panza Maurer, PA

Learning Objectives:

• Pharmacology of opiates
• Epidemiology of opioid crisis
• Current standards, laws and rules on prescribing controlled substances

Joshua Lenchus, DO, FACP, SFHM, Past President, Florida Osteopathic Medical Association

Learning Objectives:

• Define the challenges AI and robitcs present for the future of medical practice
• Identify the structural barriers medical practice faces in overcoming the disruption of AI and robotics
• Establish a framework for the future of medical practice

Seger Morris, DO, MBA, CPE, Medical Director, Molina Healthcare Mississippi

Learning Objectives:

• Identify emotional responses to clinical stressors and recognize their impact on physician decision-making, communication, and patient care.Apply at least two emotion-regulation strategies, such as STOP, slow breathing, or cognitive reappraisal, during high-stress clinical encounters.
• Apply at least two emotion-regulation strategies, such as STOP, slow breathing, or cognitive reappraisal, during high-stress clinical encounters.
• Demonstrate empathetic communication by using emotion recognition, perspective-seeking questions, culturally responsive language, and structured communication tools such as SBAR.

Antonio Graham, DO, Hospitalist/Internal Medicine, Johns Hopkins University School of Medicine

Learning Objectives:

• Reduce Misdiagnosis
• Prevent System Failures
• Create a Safety Culture

Robert T. Hasty, DO, MACOI (he/him/his), Dean & Chief Academic Officer, Orlando College of Osteopathic Medicine (Proposed)

Learning Objectives:

• Review updated algorithm guidelines including the safe exclusion of PE without CT pulmonary angiogram (CTPA).
• Identify new pulmonary embolism classification system and its impact on therapy including advanced therapies.
• Review key elements of guidelines regarding outpatient follow up for pulmonary embolism including evaluation of persistent dyspnea following PE.

Robert Schilz, DO, PhD, Medical Director of Lung Transplant and Pulmonary Vascular Disease, University Hospitals of Cleveland

Learning Objectives:

• Apply 2026 standards and guidelines for the definition and diagnosis of obesity
• Explain the pathophysiology of obesity and the relationship to lung disease
• Identify Obesity related phenotypes of COPD, asthma, OHS, OSA, pneumonia, pHTN Use current evidence to intervene early to prevent and treat obesity and lung disease

Carol E. Ash, DO (she/her/hers), Pulmonary Critical Care Sleep Medicine, Deborah Heart and Lung Center

Learning Objectives:

• Define interstitial lung abnormality and identify worrisome radiographic features
• Recognize common steroid toxicities in sarcoidosis patients and clinical scenarios where steroids are not recommended
• Associate clinical clues with higher risk of telomere disorders

Daniel Culver, DO, Chair, Pulmonary Medicine, Cleveland Clinic

Learning Objectives:

• By the end of this activity, participants will be able to: Differentiate asthma from common pulmonary and nonpulmonary causes of dyspnea by applying clinical history, physical examination, spirometry, and appropriate diagnostic testing.
• Classify patients with asthma according to relevant clinical phenotypes and inflammatory endotypes using clinical characteristics, biomarkers, pulmonary function testing, and treatment response.
• Assess patients with difficult to treat or severe asthma by identifying uncontrolled disease, modifiable factors, comorbid conditions, and features that warrant referral for specialized evaluation. Select appropriate biologic therapy for patients with severe asthma by integrating exacerbation history, biomarkers, phenotype, endotype, comorbidities, prior treatment response, and patient preferences. Develop an individualized strategy to achieve and maintain asthma control by addressing inhaler technique, adherence, environmental and comorbid factors, pharmacologic therapy, objective monitoring, and timely reassessment.

Timothy J. Barreiro, DO, MACOI, Section Chair Pulmonary, Critical care and Sleep Medicine, NEOMED, LECOM, OUHCOM

Learning Objectives:

• Upon completion, participants will be able to identify the prevalence, risk factors, and health consequences of intimate partner violence and domestic violence across diverse patient populations.
• Upon completion, participants will be able to describe validated screening tools and recognize clinical indicators that may assist in identifying patients experiencing intimate partner violence.
• Upon completion, participants will be able to demonstrate appropriate physician interventions, including patient support, safety planning, referral to community resources, and compliance with Florida reporting requirements.

Michelle Mendez, DO, HPF, FAAOE, Owner/Solo Family Physician, Mendez Family Care & Aesthetics

Learning Objectives:

• Differentiate administrative from diagnostic/clinical AI — and the differing evidence, regulatory (FDA), and liability standards each requires.
• Apply an “AI-as-intervention” framework (efficacy, harms, comparator) to evaluate a tool before adopting it.
• Identify the perils of clinical AI — hallucination & non-determinism, bias at scale, and skill erosion (de-/mis-/never-skilling) — and their mitigations.

Alex Dummett, MD (he/him/his), CEO, Socratic AI

Learning Objectives:

• Explain the concept of CAR T and immune reset.
• Understand autoimmune data for CAR T Cell therapy.
• Recognize which patients are good and poor candidates as well as possible treatment related adverse events.

Monica Shah, DO (she/her/hers), Rheumatologist, Gulf Coast Rheumatology

Learning Objectives:

• Understand HIV testing and offering of PrEP should be universal to indivdials at risk for HIV
• PrEP is effect mechanism to prevent HIV
• There are multiple options that can be tailored to patients needs

Erik Wert, DO, MPH, FACOI, AAHIVS (he/him/his), Physician, Capital Internal Medicine Associates

Learning Objectives:

• Understand autoimmune testing; it’s implications and appropriateness of testing and interpretation.
• Be familiar with the initial work up in a patient that is believed to have an autoimmune disorder; what are the first steps in commonly seen rheumatologic disorders.
• Identify rheumatological emergencies.

Mary Hinojos Mamut, DO (she/her/hers), Rheumatologist, Saint Francis Health System

This activity is supported by an educational grant from Radius Health/Paratek Pharmaceuticals

Learning Objectives:

• Apply guideline-recommended osteoporosis screening strategies to identify patients at risk for osteoporosis and fragility fractures, including older adults, men, and individuals with secondary causes of bone loss.
• Recognize fragility fractures as a sentinel event and implement timely evaluation and secondary fracture prevention strategies to reduce imminent and long-term fracture risk.
• Utilize fracture risk stratification tools to categorize patients by low, high, and very high fracture risk and translate risk assessment into evidence-based treatment decisions.

Shine Vazhappilly, MD, Rheumatologist, St. Elizabeth Healthcare